Skip to content

Exendin PET/CT for imaging of paragangliomas

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516755-40-00
Enrollment
10
Registered
2024-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

paragangliomas

Brief summary

Detection rate of PGLs (paragangliomas) using 68Ga-exendin-4 PET/CT

Detailed description

optimal timepoint for imaging PGLs using 68Ga-exendin-4 PET/CT, Comparison of quantitative imaging paramters (SUV, tumor-to-background ratio, contract-to-noise ratio) between Optimal timepoint for imaging PGLs using 68Ga-exendin-4 PET/CT, 18F-FDG PET and SSTR PET, correlation between GLP-1R expression and tracer uptake in the PGLs, Correlation quantitative imaging results and IHC data to the genetic origin of the PGLs

Interventions

DRUGEXENATIDE

Sponsors

Stichting Radboud universitair medisch centrum
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Detection rate of PGLs (paragangliomas) using 68Ga-exendin-4 PET/CT

Secondary

MeasureTime frame
optimal timepoint for imaging PGLs using 68Ga-exendin-4 PET/CT, Comparison of quantitative imaging paramters (SUV, tumor-to-background ratio, contract-to-noise ratio) between Optimal timepoint for imaging PGLs using 68Ga-exendin-4 PET/CT, 18F-FDG PET and SSTR PET, correlation between GLP-1R expression and tracer uptake in the PGLs, Correlation quantitative imaging results and IHC data to the genetic origin of the PGLs

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026